1. Scrip
  2. >>Business

High-Flying Biotech Valuations Are Falling – And Maybe That’s A Good Thing

Big Pharma Focused On Science, Not Prior Funding

 
• By Mandy Jackson

Venture capitalists speaking at Biocom’s Global Life Science Partnering Conference looked forward to a return to rational valuations that could enable better returns for investors and pharma buyers.

Passenger airplane is flying in colorful sky at sunset
The sun is setting on high biotech valuations this year • Source: Alamy

Venture capital investors speaking at Biocom’s Global Life Science Partnering Conference did not exactly cheer declining biotechnology company valuations but they welcomed a return to more rational valuations that could justify further fundraising and deal-making at terms that make sense for investors and big pharma buyers.

“In the private investing area, I actually think this is a good thing that we're going to have some rationalization...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.